PUBLISHER: The Business Research Company | PRODUCT CODE: 1694844
PUBLISHER: The Business Research Company | PRODUCT CODE: 1694844
Proliferative diabetic retinopathy (PDR) represents an advanced stage of diabetic eye disease marked by the development of abnormal blood vessels in the retina. This occurrence is primarily attributed to prolonged high levels of blood sugar. If left unaddressed, these abnormal vessels can result in retinal bleeding, scarring, and impaired vision. Consequently, regular eye examinations are of paramount importance for early detection and effective management.
The primary treatment options for proliferative diabetic retinopathy encompass anti-VEGF (vascular endothelial growth factor) therapy, intraocular steroids, laser surgery, and vitrectomy. Intraocular steroids involve the direct administration of medications into the eye, which serves to address inflammation and manage conditions like diabetic macular edema or uveitis. This approach aids in reducing swelling and enhancing visual outcomes. Various modes of administration, including injectables, oral medications, and others, find application in settings such as hospitals, clinics, and more.
The proliferative diabetic retinopathy market research report is one of a series of new reports from The Business Research Company that provides proliferative diabetic retinopathy market statistics, including proliferative diabetic retinopathy industry global market size, regional shares, competitors with a proliferative diabetic retinopathy market share, detailed proliferative diabetic retinopathy market segments, market trends and opportunities and any further data you may need to thrive in the proliferative diabetic retinopathy industry. This proliferative diabetic retinopathy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The proliferative diabetic retinopathy (PDR) market size has grown rapidly in recent years. It will grow from $2.42 billion in 2024 to $2.7 billion in 2025 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to growing diabetes prevalence, changes in lifestyle and intake of unhealthy foods, government initiatives, rising numbers of diabetes-related loss of vision.
The proliferative diabetic retinopathy (PDR) market size is expected to see rapid growth in the next few years. It will grow to $4.02 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to aging population, public awareness and education about diabetes, research and development funding, rising demand for combination therapies. Major trends in the forecast period include advancements in diagnostic technologies, innovations in treatment options, artificial intelligence (AI) for early diagnosis, gene therapy advancements, advanced retinal imaging.
The increasing prevalence of diabetes is anticipated to drive growth in the proliferative diabetic retinopathy (PDR) market. Diabetes, a chronic condition marked by elevated blood glucose levels, is the primary cause of proliferative diabetic retinopathy, which can be managed with treatments that prevent further retinal damage and help preserve vision. For example, in June 2024, data from the UK's National Health Service (NHS) showed a rise in diabetes cases among individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This notable increase underscores a concerning trend in younger populations. Consequently, the rising diabetes prevalence is a key factor driving the PDR market forward.
The increasing prevalence of obesity is expected to be a key driver for the future growth of the proliferative diabetic retinopathy (PDR) market. Obesity, a multifaceted, chronic condition with various contributing factors, results in an excess accumulation of body fat and potential health issues. Obesity is closely associated with insulin resistance, chronic low-grade inflammation, and heightened oxidative stress, all of which can adversely affect the retinal microvasculature and contribute to the onset of diabetic retinopathy. For instance, according to a 2022 report released by Trust for America's Health, a non-profit organization in the United States, obesity rates in the country are on the rise, with four out of every ten American adults being affected by obesity. This represents an increase compared to the previous year, with 19 states reporting adult obesity rates exceeding 35%, up from 16 states in the preceding year. Consequently, the escalating prevalence of obesity serves as a pivotal catalyst driving the expansion of the proliferative diabetic retinopathy (PDR) market.
Prominent companies operating in the proliferative diabetic retinopathy market maintain a consistent focus on the development of groundbreaking therapies. This strategic emphasis aims to enhance treatment efficacy, alleviate the treatment-related financial burden, and ultimately elevate patient outcomes. For instance, in June 2022, Biogen, a leading US-based biotechnology company, partnered with Samsung Bioepis, a South Korea-based biotech company, to introduce Byooviz (ranibizumab-nuna). Byooviz represents the first ophthalmology biosimilar in the United States, offering treatment options for patients dealing with diabetic macular edema, proliferative diabetic retinopathy, neovascular age-related macular degeneration (wet AMD), and choroidal neovascularization. These innovative therapies are poised to bring transformative changes to the landscape of proliferative diabetic retinopathy treatment.
In July 2024, Merck & Co., Inc., a U.S.-based healthcare company specializing in medicines, vaccines, and animal health products, acquired Eyebiotech Limited for $3 billion. Through this acquisition, Merck aims to strengthen its ophthalmology pipeline by advancing innovative treatments for sight-threatening retinal diseases and addressing critical unmet needs in this field. Eyebiotech Limited, a UK-based biotechnology company, focuses on developing therapies for proliferative diabetic retinopathy to counteract abnormal retinal blood vessel growth.
Major companies operating in the proliferative diabetic retinopathy (pdr) market are Pfizer Inc., Johnson and Johnson Limited, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Merck KGaA, Kubota Vision Inc., Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Mylan N.V., Santen Pharmaceutical Co. Ltd., Lupin Limited, Genentech Inc., Sirnaomics Inc.
North America was the largest region in the proliferative diabetic retinopathy market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in proliferative diabetic retinopathy (PDR) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the proliferative diabetic retinopathy (PDR) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The proliferative diabetic retinopathy (PDR) market consists of sales of laser therapy, systemic therapies and combination therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The proliferative diabetic retinopathy (PDR) market also includes sales of corticosteroids, ranibizumab, bevacizumab and fluocinolone acetonide drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Proliferative Diabetic Retinopathy (PDR) Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on proliferative diabetic retinopathy (pdr) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for proliferative diabetic retinopathy (pdr) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The proliferative diabetic retinopathy (pdr) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.